Cargando…
Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy)
Background. Allergic patients may develop reactions following COVID-19 vaccination more frequently than non-allergic individuals. The aim of our study was to assess the risk of reactions in high-risk allergic patients vaccinated for COVID-19 at the University Health Agency Giuliano-Isontina (ASUGI)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607499/ https://www.ncbi.nlm.nih.gov/pubmed/36298481 http://dx.doi.org/10.3390/vaccines10101616 |
_version_ | 1784818560264044544 |
---|---|
author | Filon, Francesca Larese Lazzarato, Ilaria Patriarca, Emilia Iavernig, Thomas Peratoner, Alberto Perri, Giuseppe Ponis, Giuliano Rocco, Giulio Cegolon, Luca |
author_facet | Filon, Francesca Larese Lazzarato, Ilaria Patriarca, Emilia Iavernig, Thomas Peratoner, Alberto Perri, Giuseppe Ponis, Giuliano Rocco, Giulio Cegolon, Luca |
author_sort | Filon, Francesca Larese |
collection | PubMed |
description | Background. Allergic patients may develop reactions following COVID-19 vaccination more frequently than non-allergic individuals. The aim of our study was to assess the risk of reactions in high-risk allergic patients vaccinated for COVID-19 at the University Health Agency Giuliano-Isontina (ASUGI) of Trieste (northeastern Italy). Methods. Patients were considered at high risk for allergic reactions in case of: prior anaphylactic reaction to any drug/vaccine; multiple drug allergy; intolerance to polyethylene glycol (PEG) or polysorbate 80 (PS80) containing drugs; and mast cell disorders. High-risk allergic patients were immunized in hospital by a dedicated allergy team supported by resuscitation staff. Patients were interviewed over the phone one month after vaccination to complete a structured questionnaire investigating signs and symptoms developed after immunization. Results. From March 2021 to February 2022, 269 patients with a history of severe allergic reactions were assessed, of whom 208 (77.3%) eventually received COVID-19 vaccination, 50 (18.6%) refused to be immunized, 10 (3.7%) were deferred for medical reasons and one was declared exempted due to testing positive for PS80. Mild reactions (urticaria, angioedema, rhinitis, erythema) to COVID-19 vaccines were reported by 30.3% of patients, 8.7% within 4 h and 21.6% > 4 h after immunization. No anaphylactic events were observed. Although they were 80 times (3.8%) more prevalent than in COVID-19 vaccinees from the general population (0.047%), vaccine allergic reactions in high-risk patients were mainly mild and late, more likely affecting women (OR = 3.05; 95% CI 1.22–7.65). Conclusions. High-risk allergic patients with urticaria and angioedema may experience mild flare-ups of mast cell activation-like symptoms following COVID-19 vaccination, supporting antihistamine premedication before vaccination and to be continued for one week afterwards. |
format | Online Article Text |
id | pubmed-9607499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96074992022-10-28 Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) Filon, Francesca Larese Lazzarato, Ilaria Patriarca, Emilia Iavernig, Thomas Peratoner, Alberto Perri, Giuseppe Ponis, Giuliano Rocco, Giulio Cegolon, Luca Vaccines (Basel) Article Background. Allergic patients may develop reactions following COVID-19 vaccination more frequently than non-allergic individuals. The aim of our study was to assess the risk of reactions in high-risk allergic patients vaccinated for COVID-19 at the University Health Agency Giuliano-Isontina (ASUGI) of Trieste (northeastern Italy). Methods. Patients were considered at high risk for allergic reactions in case of: prior anaphylactic reaction to any drug/vaccine; multiple drug allergy; intolerance to polyethylene glycol (PEG) or polysorbate 80 (PS80) containing drugs; and mast cell disorders. High-risk allergic patients were immunized in hospital by a dedicated allergy team supported by resuscitation staff. Patients were interviewed over the phone one month after vaccination to complete a structured questionnaire investigating signs and symptoms developed after immunization. Results. From March 2021 to February 2022, 269 patients with a history of severe allergic reactions were assessed, of whom 208 (77.3%) eventually received COVID-19 vaccination, 50 (18.6%) refused to be immunized, 10 (3.7%) were deferred for medical reasons and one was declared exempted due to testing positive for PS80. Mild reactions (urticaria, angioedema, rhinitis, erythema) to COVID-19 vaccines were reported by 30.3% of patients, 8.7% within 4 h and 21.6% > 4 h after immunization. No anaphylactic events were observed. Although they were 80 times (3.8%) more prevalent than in COVID-19 vaccinees from the general population (0.047%), vaccine allergic reactions in high-risk patients were mainly mild and late, more likely affecting women (OR = 3.05; 95% CI 1.22–7.65). Conclusions. High-risk allergic patients with urticaria and angioedema may experience mild flare-ups of mast cell activation-like symptoms following COVID-19 vaccination, supporting antihistamine premedication before vaccination and to be continued for one week afterwards. MDPI 2022-09-27 /pmc/articles/PMC9607499/ /pubmed/36298481 http://dx.doi.org/10.3390/vaccines10101616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Filon, Francesca Larese Lazzarato, Ilaria Patriarca, Emilia Iavernig, Thomas Peratoner, Alberto Perri, Giuseppe Ponis, Giuliano Rocco, Giulio Cegolon, Luca Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title | Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title_full | Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title_fullStr | Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title_full_unstemmed | Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title_short | Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) |
title_sort | allergic reactions to covid-19 vaccination in high-risk allergic patients: the experience of trieste university hospital (north-eastern italy) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607499/ https://www.ncbi.nlm.nih.gov/pubmed/36298481 http://dx.doi.org/10.3390/vaccines10101616 |
work_keys_str_mv | AT filonfrancescalarese allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT lazzaratoilaria allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT patriarcaemilia allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT iavernigthomas allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT peratoneralberto allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT perrigiuseppe allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT ponisgiuliano allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT roccogiulio allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly AT cegolonluca allergicreactionstocovid19vaccinationinhighriskallergicpatientstheexperienceoftriesteuniversityhospitalnortheasternitaly |